New pill shows promise against Hard-to-Treat cancers in early trial
Disease control
Completed
This early-stage study tested a new drug called RP903 in 69 people with advanced ovarian, breast, endometrial, cervical, or other solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the best dose, and see if it cou…
Phase: PHASE1 • Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. • Aim: Disease control
Last updated May 03, 2026 09:06 UTC